Horizon CEO Joel White spoke with Politico about the new Speaker of the House, where he stands on healthcare, and the important role committee leaders will play in pushing through […]
More and more states are mirroring federal policies on drugs. States have expanded their sights to regulate PBMs, drug access, and drug manufacturers. 2024 promises to bring even more efforts […]
For Immediate Release October 30, 2023Contact: Anna Nix Kumar(605) 201-7702akumar@monumentadvocacy.com Monument Partner John Murray: “Nicole will amplify, extend, and expand our firm’s unique mix of government relations, public affairs and […]
Horizon’s CEO, Joel White, recently had lunch with Peter Sullivan where he shared stories about his time working in Congress and his favorite places to go to on Capitol Hill. […]
Managed Healthcare Executive quoted Horizon’s Joel White in an article about Medicare drug price negotiations. Politico quoted Joel White, whom it identified as a Republican healthcare strategist, as saying that […]
Politico interviewed Joel White on today’s release of the ten drugs subject to government price controls and how Republicans can respond. ““The price control is a huge departure from where […]
Horizon’s CEO spoke with The Washington Times about today’s release of the ten drugs subject to Medicare price negotiations. ““It’s all wine and roses today — there’s no downside. What […]
Earlier this summer, the U.S. Department of Health and Human Services (HHS) released its final rule implementing information blocking penalties for some actors, and a rule impacting providers is expected […]
The Waste Watcher cited Horizon’s research on how pharmaceutical companies are responding to the upcoming release of the list of 10 drugs that will be subject to Medicare price negotiations. […]